Isabel Arrillaga‐Romany

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.3K citations

Neuro-oncology, Neoadjuvant Anti-pd-1 Immunotherapy, Tumor Immunology +14

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Philipp Karschnia, Justin T. Jordan, Deborah Forst et al. · Blood · 2019 · 329 citations · Full text

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen et al. · Nature Medicine · 2023 · 191 citations · Full text

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Ilon Liu, Li Jiang, Erik Samuelsson et al. · Nature Genetics · 2022 · 173 citations · Full text

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

Isabel Arrillaga‐Romany, S. Andrew, Joshua E. Allen et al. · Oncotarget · 2017 · 160 citations · Full text